Hoth Therapeutics Inc Asset Resilience Ratio
Hoth Therapeutics Inc asset resilience ratio. Hoth Therapeutics Inc (HOTH) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hoth Therapeutics Inc (HOTH) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hoth Therapeutics Inc (2019–2025)
Asset resilience ratio of Hoth Therapeutics Inc from 2019 to 2025. This chart shows how Hoth Therapeutics Inc's Asset Resilience Ratio has changed over time. Read HOTH total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hoth Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see HOTH total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Hoth Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Hoth Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Hoth Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Hoth Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Hoth Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Hoth Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.52% | $191.37K | $7.60 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $7.71 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $10.24 Million | -- |
| 2022-12-31 | 3.10% | $209.32K | $6.76 Million | -14.13pp |
| 2021-12-31 | 17.23% | $1.89 Million | $10.99 Million | -22.12pp |
| 2020-12-31 | 39.35% | $2.06 Million | $5.24 Million | +11.02pp |
| 2019-12-31 | 28.34% | $803.66K | $2.84 Million | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more